PRESS RELEASE: Accenture and Bristol-Myers Squibb Launch Pharmaceutical Industry’s First Joint Center for Pharmacovigilance

Accenture and Bristol-Myers Squibb Launch Pharmaceutical Industry’s First Joint Center for Pharmacovigilance

NEW YORK; Sept 13, 2007 -- Accenture and Bristol-Myers Squibb Company today launched in Chennai, India, the pharmaceutical industry’s first joint center for pharmacovigilance.  Pharmacovigilance is the monitoring of safety data to ensure optimal use of medicines. It entails the capture, assessment, and reporting of potential side effects to medicines.

Operated by more than 140 Accenture employees, the new center will undertake the processing and coding of adverse event data and the generation of regulatory periodic and aggregate reports on safety as well as physician medical review of adverse events.

This is the first time a collaboration for ‘end-to-end’ safety case processing has been established and is inclusive of specialized activities, such as medical review of the reported adverse reactions.  The team is organized as a parallel process and extension of the Bristol-Myers Squibb pharmacovigilance headquarters’ operations. It allows for the seamless handling of data and reports between Accenture and Bristol-Myers Squibb while not compromising patient safety.

“Building a joint team with a specialized focus will support the continued growth of our robust product pipeline, improving scalability and increasing overall productivity,” said John Balian, M.D., senior vice president, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb.  “Working with Accenture, Bristol-Myers Squibb will continue to access world-class talent to deliver on our regulatory obligations, while enhancing our focus on patient safety.”

“Leading companies are re-thinking their operating model to drive sustainable growth and productivity,” said Eric Sandor, managing director of Accenture Pharmacovigilance Services.  “Through a truly collaborative partnership with Bristol-Myers Squibb we have established an industry leading operation that is delivering substantial efficiency and improved flexibility for Bristol-Myers Squibb’s pharmacovigilance organization.”

The pharmacovigilance center is part of Accenture’s Life Sciences Centers of Excellence in Bangalore and Chennai that Bristol-Myers Squibb already utilizes.  Part of the multi-year R&D agreement signed in April this year, the pharmacovigilance center furthers Bristol-Myers Squibb’s efforts to significantly expand its R&D capabilities in India as an integral part of the company’s overall global strategy.

About Accenture

Accenture is a global management consulting, technology services and outsourcing company.  Committed to delivering innovation, Accenture collaborates with its clients to help them become high-performance businesses and governments.  With deep industry and business process expertise, broad global resources and a proven track record, Accenture can mobilize the right people, skills and technologies to help clients improve their performance.  With more than 158,000 people in 49 countries, the company generated net revenues of US$16.65 billion for the fiscal year ended Aug. 31, 2006.  Its home page is

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.